Novo Nordisk A/S
Novo Nordisk A/S（NONOF）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
nonof · 股价预测 · 25 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 25 位华尔街分析师
Buy
25 位分析师
共识
评级分布
12 个月目标价
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $42.27
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $41.43 | ↓ 1.98% |
1-day model range: $41.27–$41.59. Peak: $41.59 (-1.98%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $38 | -9.2% |
| 2028 | $36 | -14.6% |
| 2029 | $35 | -17.9% |
| 2030 | $34 | -20.0% |
| 2031 | — | -21.3% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NONOF · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-03-27 | BTIG | Maintains | Buy→Buy |
| 2022-12-11 | TD Cowen | Maintains | Outperform→Outperform |
| 2022-06-27 | UBS | Downgrade ↓ | Neutral→Sell |
| 2022-06-06 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
| 2022-05-30 | Guggenheim | Upgrade ↑ | Neutral→Buy |
| 2022-03-15 | Deutsche Bank | Upgrade ↑ | Hold→Buy |
| 2022-01-24 | Liberum | Downgrade ↓ | Hold→Sell |
| 2021-12-19 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2020-01-02 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2019-11-17 | Barclays | Upgrade ↑ | Equal Weight→Overweight |
Wall Street analysts have recently issued updated ratings on Novo Nordisk A/S (NONOF) stock. Of the recent 52 rating actions, 25 were upgrades and 22 were downgrades. 25 analysts currently cover NONOF.
分析师推荐趋势
NONOF analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$292.2B
↓ 8.7% YoY
Revenue Next Year
$299.4B
↑ 2.5% YoY
EPS This Year
$21.68
EPS Next Year
$21.46
↓ 1.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast NONOF EPS of $21.68 for the current fiscal year, based on estimates from 1 analysts. The NONOF revenue forecast is $292.2B for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
NONOF 股价预测由两类独立数据源支撑：来自 25 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。NONOF 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。
NONOF 的短期预测（明日）为 $41.43（-1.98%）。 NONOF 对 2027 年的股价预测均值为 $38。 NONOF 对 2030 年的预测区间为 $32–$35。
Novo Nordisk A/S 在 OTC 上市，代码 NONOF。NONOF 在 2027 年的整体展望偏积极，在覆盖分析师中约 72% 对应 Buy 共识。
常见问题
NONOF 预测 · 8 个问题根据 25 位华尔街分析师，NONOF 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $42.27，隐含约 +0.0% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.